Search Results

You are looking at 101 - 109 of 109 items for :

  • "cardiac hypertrophy" x
Clear All
Free access

Emmely M de Vries, Eric Fliers and Anita Boelen

1591 – 1598 . ( doi:10.1210/endo.137.5.8612490 ) Wassen FW Schiel AE Kuiper GG Kaptein E Bakker O Visser TJ Simonides WS 2002 Induction of thyroid hormone-degrading deiodinase in cardiac hypertrophy and failure . Endocrinology 143

Free access

Sujith Rajan, Ganesh Panzade, Ankita Srivastava, Kripa Shankar, Rajesh Pandey, Durgesh Kumar, Sanchita Gupta, Abhishek Gupta, Salil Varshney, Muheeb Beg, Raj Kumar Mishra, Ravi Shankar and Anil Gaikwad

10.1016/j.bbrc.2004.12.026 Li Y Cai X Guan Y Wang L Wang S Fu Y Gao X Su G 2016 Adiponectin upregulates MiR-133a in cardiac hypertrophy through AMPK activation and reduced ERK1/2 phosphorylation . PLoS ONE 11 e0148482 . ( https://doi.org/10

Free access

Ivana Vaněčková, Lenka Maletínská, Michal Behuliak, Veronika Nagelová, Josef Zicha and Jaroslav Kuneš

progressively; animals also develop cardiac hypertrophy and vascular disease ( Ernsberger et al . 2007 ). Thus, one can say that obesity precedes hypertension, but it is difficult to say that obesity is a cause of hypertension in this model. Obese Zucker rats

Free access

Cyril S Anyetei-Anum, Vincent R Roggero and Lizabeth A Allison

. Wadosky KM Berthiaume JM Tang W Zungu M Portman MA Gerdes AM Willis MS 2016 MuRF1 mono-ubiquitinates TRα to inhibit T3-induced cardiac hypertrophy in vivo . Journal of Molecular Endocrinology 56 273 – 290 . ( https://doi.org/10

Free access

Stefanie Ruhs, Alexander Nolze, Ralf Hübschmann and Claudia Grossmann

aldosterone/MR in the heart mimic those of the vasculature and include inflammation, fibrosis, cardiac hypertrophy and electrical remodeling. In ischemia-reperfusion experiments of the heart, aldosterone and low concentrations of cortisol both led to

Free access

Yolanda Diz-Chaves, Manuel Gil-Lozano, Laura Toba, Juan Fandiño, Hugo Ogando, Lucas C González-Matías and Federico Mallo

AMPK pathway, which enhances glycogen storage, and may provoke cardiac hypertrophy and ventricular arrhythmias. From these data, it can be inferred that increased GCs in diabetes might also contribute to higher cardiovascular risk ( Wu et al. 2004

Free access

Emilio Hirsch, Carlotta Costa and Elisa Ciraolo

of MCIP1, a negative regulator of the NFAT transcription factor involved in cardiac hypertrophy ( Pedram et al. 2005 ). PI3K in Ang II signaling PI3K might also play a role in the signaling pathways triggered

Free access

Shui-lin Sun and Liang-ming Liu

cardiac function and attenuated cardiac hypertrophy in experimental heart failure . European Journal of Pharmacology 799 94 – 102 . ( https://doi.org/10.1016/j.ejphar.2017.02.003 ) 10.1016/j.ejphar.2017.02.003 28163023 Onat AM Turkbeyler IH Pehlivan

Free access

Mohammed Bensellam, Jean-Christophe Jonas and D Ross Laybutt

the progression of cardiac hypertrophy and heart failure in vivo . Journal of Translational Medicine 13 363 . ( https://doi.org/10.1186/s12967-015-0725-4 ) 10.1186/s12967-015-0725-4 26572862 Duan JJ Cai J Guo YF Bian XW Yu SC